Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.

Tamai H, Mori Y, Shingaki N, Kawashima A, Tsukuda H, Higashi K, Moribata K, Kawaguchi M, Ueda K, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M.

Antivir Ther. 2014;19(1):107-15. doi: 10.3851/IMP2696. Epub 2013 Oct 25.

PMID:
24162072
[PubMed - in process]
2.

Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation.

Tamai H, Shingaki N, Shiraki T, Tukuda H, Mori Y, Moribata K, Enomoto S, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M.

Hepatol Res. 2011 Dec;41(12):1137-44. doi: 10.1111/j.1872-034X.2011.00879.x. Epub 2011 Sep 26.

PMID:
21951330
[PubMed]
3.

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H.

Liver Int. 2011 Oct;31(9):1359-65. doi: 10.1111/j.1478-3231.2011.02571.x. Epub 2011 Jun 23.

PMID:
21745312
[PubMed - indexed for MEDLINE]
4.

Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.

Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.

J Viral Hepat. 2011 Apr;18(4):280-6. doi: 10.1111/j.1365-2893.2010.01305.x.

PMID:
20367792
[PubMed - indexed for MEDLINE]
5.

Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.

Yen YH, Hung CH, Hu TH, Chen CH, Wu CM, Wang JH, Lu SN, Lee CM.

Aliment Pharmacol Ther. 2008 Jan 1;27(1):72-9. Epub 2007 Oct 25.

PMID:
17973647
[PubMed - indexed for MEDLINE]
Free Article
6.

Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.

Miyasaka A, Kumagai I, Abe K, Suzuki K.

Hepatogastroenterology. 2012 May;59(115):794-9. doi: 10.5754/hge11570.

PMID:
22020909
[PubMed - indexed for MEDLINE]
7.

Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.

Aziz H, Raza A, Waheed Y, Gill U, Gill ML.

Int J Infect Dis. 2012 Aug;16(8):e597-602. doi: 10.1016/j.ijid.2012.03.012. Epub 2012 Jun 1.

PMID:
22658873
[PubMed - indexed for MEDLINE]
Free Article
8.

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.

Nakagawa M, Sakamoto N, Ueyama M, Mogushi K, Nagaie S, Itsui Y, Azuma S, Kakinuma S, Tanaka H, Enomoto N, Watanabe M.

J Gastroenterol. 2010 Jun;45(6):656-65. doi: 10.1007/s00535-009-0195-7. Epub 2010 Jan 30.

PMID:
20112032
[PubMed - indexed for MEDLINE]
9.

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H.

J Gastroenterol. 2012 Oct;47(10):1143-51. doi: 10.1007/s00535-012-0578-z. Epub 2012 Mar 24.

PMID:
22441534
[PubMed - indexed for MEDLINE]
10.

Low-dose pegylated interferon-alpha-2a monotherapy in elderly and/or cirrhotic patients infected with hepatitis C virus genotype-2 or genotype-1 low level infection.

Tamai H, Moribata K, Mori Y, Shingaki N, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M.

Hepatol Res. 2013 Jul;43(7):702-8. doi: 10.1111/hepr.12024. Epub 2012 Dec 17.

PMID:
23252609
[PubMed]
11.

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2009 Mar;81(3):452-8. doi: 10.1002/jmv.21400.

PMID:
19152407
[PubMed - indexed for MEDLINE]
12.

Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.

Larrey D, Carenco C, Guyader D, Boyer N, Benhamou Y, Pageaux GP, Rouzier R, Marcellin P.

Antivir Ther. 2012;17(5):927-32. doi: 10.3851/IMP2126. Epub 2012 May 18.

PMID:
22611092
[PubMed - indexed for MEDLINE]
13.

Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.

Hayashi K, Katano Y, Ishuzu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H.

J Gastroenterol Hepatol. 2014 Jul 3. doi: 10.1111/jgh.12673. [Epub ahead of print]

PMID:
24995561
[PubMed - as supplied by publisher]
14.

Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B.

Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.

Hepatol Res. 2013 Jun;43(6):580-8. doi: 10.1111/hepr.12005. Epub 2013 Jan 29.

PMID:
23356752
[PubMed]
15.

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.

J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.

PMID:
21129805
[PubMed - indexed for MEDLINE]
16.

Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks.

Wada Y, Tamai H, Uno A, Kawashima A, Shingaki N, Mori Y, Moribata K, Miyata K, Higashi K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M.

Hepatol Res. 2014 Feb;44(2):179-86. doi: 10.1111/hepr.12101. Epub 2013 Mar 27.

PMID:
23531032
[PubMed]
17.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
[PubMed - indexed for MEDLINE]
18.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
[PubMed - indexed for MEDLINE]
19.

Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.

El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, Hotta H.

PLoS One. 2012;7(2):e30513. doi: 10.1371/journal.pone.0030513. Epub 2012 Feb 2.

PMID:
22319571
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk